|
시장보고서
상품코드
2078865
피부암 치료제 시장 : 약제 유형별, 암 유형별, 투여 경로별, 유통 채널별, 지역별Skin Cancer Drugs Market, By Drug Type, By Cancer Type, By Route of Administration, By Distribution Channel, By Geography |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
피부암 치료제 시장은 2026년에 111억 8,000만 달러, 2033년까지 197억 8,000만 달러에 이를 것으로 예상됩니다. 또한, 2026-2033년 CAGR 8.5%를 기록할 전망입니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 111억 8,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 예측 기간(2026-2033년) CAGR : | 8.50% | 2033년 시장 규모 예측 : | 197억 8,000만 달러 |
세계 피부암 치료제 시장에는 화학요법제, 표적 치료제, 면역요법제 및 이와 유사한 유형의 약제가 포함됩니다. 이 약들은 기저세포암, 편평상피암, 악성 흑색종, 기타(카포시 육종, 균상 육아종 등)의 치료에 사용되며, 병원 약국이나 소매 약국에서 처방되고 있습니다. 조직이 실적, 효율성, 비용 대비 효과를 점점 더 중시함에 따라, 이러한 부문에서의 채용은 꾸준히 확대되고 있습니다.
시장 역학:
병원 약국 및 소매 약국 수요 증가, 효율성과 신뢰성 향상의 필요성, 그리고 지속적인 제품 혁신이 전 세계 피부암 치료제 시장의 성장을 견인할 것으로 예상되는 주요 요인입니다. 기저세포암과 편평상피암에서의 적용 범위가 확대되면서 이러한 추세가 더욱 가속화되고 있습니다.
예를 들어, 시장에 진출한 각 기업은 기저세포암 치료 사례를 위해 설계된 첨단 솔루션을 도입하고 있습니다. 또한, 지속적인 기술 발전과 전략적 투자를 통해 예측 기간 동안 시장에 진출한 기업들에게 새로운 성장 기회가 창출될 것으로 전망됩니다.
본 조사의 주요 특징:
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업들이 채택하는 경쟁 전략에 관한 중요한 인사이트를 제공합니다.
- 본 조사에서는 기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략 등의 지표를 바탕으로 전 세계 피부암 치료제 시장의 주요 기업 프로파일을 소개했습니다.
- 본 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 대해 정보에 입각한 의사결정을 내릴 수 있게 됩니다.
- "세계의 피부암 치료제 시장” 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진출기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자 여러분은 전 세계 피부암 치료제 시장 분석에 활용된 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 피부암 치료제 시장 : 약제 유형별, 2021년-2033년
제5장 세계의 피부암 치료제 시장 : 암 유형별, 2021년-2033년
제6장 세계의 피부암 치료제 시장 : 투여 경로별, 2021년-2033년
제7장 세계의 피부암 치료제 시장 : 유통 채널별, 2021년-2033년
제8장 세계의 피부암 치료제 시장 : 지역별, 2021년-2033년
제9장 경쟁 구도
제10장 섹션
LSH 26.07.10Skin Cancer Drugs Market is estimated to be valued at USD 11.18 Bn in 2026 and is expected to reach USD 19.78 Bn by 2033, growing at a compound annual growth rate (CAGR) of 8.5% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 11.18 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 8.50% | 2033 Value Projection: | USD 19.78 Bn |
The global skin cancer drugs market includes offerings that span Chemotherapy Drugs, Targeted Therapy Drugs, and Immunotherapy Drugs, and similar drug type categories. These are applied across Basal cell carcinoma, Squamous cell carcinoma, and Melanoma and Others (Kaposi's sarcoma, Mycosis fungoides and Others) and adopted by Hospital Pharmacies, and Retail Pharmacies. As organizations increasingly prioritize performance, efficiency, and cost-effectiveness, adoption across these segments continues to grow steadily.
Market Dynamics:
Increasing demand from Hospital Pharmacies, and Retail Pharmacies, the need for improved efficiency and reliability, and ongoing product innovation are major factors expected to drive growth of the global skin cancer drugs market. Broader adoption across Basal cell carcinoma, and Squamous cell carcinoma is reinforcing this momentum.
For instance, market players are introducing advanced solutions designed for Basal cell carcinoma use cases. Moreover, continued technological advancement and strategic investment are expected to create new growth opportunities for market players over the forecast period.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global skin cancer drugs market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Novartis, Merck, Roche, Amgen, Pfizer, Sun Pharma, Bristol-Myers Squibb, AstraZeneca, Johnson & Johnson, Valeant, Daiichi Sankyo, Takeda, LEO Pharma, Mylan, Sanofi, Regeneron, Eli Lilly, Bayer, Gilead Sciences, and Astellas Pharma, among others.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global skin cancer drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global skin cancer drugs market.
Detailed Segmentation:
- Global Skin Cancer Drugs Market, By Drug Type (Revenue, USD Bn, 2021 - 2033)
- Chemotherapy Drugs
- Targeted Therapy Drugs
- Immunotherapy Drugs
- Hormone Therapy Drugs and Others (Photodynamic Therapy, Cryotherapy and Others)
- Global Skin Cancer Drugs Market, By Cancer Type (Revenue, USD Bn, 2021 - 2033)
- Basal cell carcinoma
- Squamous cell carcinoma
- Melanoma and Others (Kaposi's sarcoma, Mycosis fungoides and Others)
- Global Skin Cancer Drugs Market, By Route of Administration (Revenue, USD Bn, 2021 - 2033)
- Topical
- Oral
- Injectable and Others (Surgical procedures, radiation therapy and Others)
- Global Skin Cancer Drugs Market, By Distribution Channel (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Company Profiles:
- Novartis*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Merck
- Roche
- Amgen
- Pfizer
- Sun Pharma
- Bristol-Myers Squibb
- AstraZeneca
- Johnson & Johnson
- Valeant
- Daiichi Sankyo
- Takeda
- LEO Pharma
- Mylan
- Sanofi
- Regeneron
- Eli Lilly
- Bayer
- Gilead Sciences
- Astellas Pharma
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Cancer Type
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Increasing incidence of skin cancers
- High costs of targeted therapies
- Combination therapies
- Key Highlights
- Regulatory Scenario
- Recent Trends
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Mergers, Acquisitions, and Collaborations
4. Global Skin Cancer Drugs Market, By Drug Type, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Chemotherapy Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Targeted Therapy Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Immunotherapy Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Hormone Therapy Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Others (Photodynamic Therapy, Cryotherapy and Others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
5. Global Skin Cancer Drugs Market, By Cancer Type, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Basal cell carcinoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Squamous cell carcinoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Melanoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Others (Kaposi's sarcoma, Mycosis fungoides and Others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
6. Global Skin Cancer Drugs Market, By Route of Administration, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Topical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Others (Surgical procedures, radiation therapy and Others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
7. Global Skin Cancer Drugs Market, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
8. Global Skin Cancer Drugs Market, By Region, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, By Sub-region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Sub-region, 2022 -2033
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2021 - 2033,(US$ Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2021 - 2033,(US$ Bn)
- South Africa
- North Africa
- Central Africa
9. Competitive Landscape
- Company Profile
- Novartis
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Roche
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Amgen
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Pfizer
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sun Pharma
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Bristol-Myers Squibb
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- AstraZeneca
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Valeant
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Daiichi Sankyo
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Takeda Pharmaceutical
- Company Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- LEO Pharma
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Mylan N.V.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Regeneron
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Eli Lilly
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Bayer
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Gilead Sciences
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Astellas Pharma
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Novartis
- Analyst Views
10. Section
- References
- Research Methodology
- About us
